A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)
Simple Imaging Versus Standard Imaging Selection in Stroke Patients for Endovascular Treatment: the NO-SELECT Randomized Trial
1 other identifier
interventional
1,846
1 country
8
Brief Summary
Several studies suggest that advanced multi-modal imaging with CTP should be used to screen late time window stroke patients for thrombectomy. However, NCCT is more accessible when comparing with CTP. It is unclear whether the NCCT-based ASPECTS can be used as an imaging criterion to screen patients for thrombectomy. The newly published MR CLEAN-LATE and TENSION trials used NCCT or CTA, but still relied on ASPECTS scores to evaluate and select patients for endovascular therapy. However, different trials have different time windows. The aim of this trial was to assess the clinical outcomes of stroke patients with anterior large vessel occlusion who selected by simple imaging (NCCT) comparing via standard imaging screening strategy (CTP/MRI). The hypothesis is that simple imaging is non-inferior to standard imaging selection strategy in terms of achieving favorable outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2024
Typical duration for not_applicable
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 27, 2022
CompletedFirst Posted
Study publicly available on registry
February 9, 2022
CompletedStudy Start
First participant enrolled
December 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 31, 2027
December 26, 2025
December 1, 2025
2.5 years
January 27, 2022
December 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
favorable outcome at 90 days
defined as modified Rankin scale score of 0 to 3. Modified Rankin scale score (mRS): scores range from 0 to 6, with 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death.
90 days post-endovascular treatment
Secondary Outcomes (2)
symptomatic intracranial hemorrhage within 48 hours
within 48 hours post-endovascular treatment
mortality at 90 days
90 days post-endovascular treatment
Study Arms (2)
Simple imaging
EXPERIMENTALNCCT and CTA will be used to screen patients for endovascular treatment
Standard imaging
ACTIVE COMPARATORNCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
Interventions
NCCT and CTA will be used to screen patients for endovascular treatment
NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
Eligibility Criteria
You may qualify if:
- Aged 18 years or older;
- The interval time from last known well to hospital arrival is within 24 hours;
- Acute stroke confirmed by clinical symptoms or imaging examination;
- Field Assessment Stroke Triage for Emergency Destination (FAST ED) ≥4;
- Written informed consent is obtained from patients and/or their legal representatives.
You may not qualify if:
- Allergy to radiographic contrast agents, or nitinol devices;
- Currently pregnant or lactating (women patients);
- Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel;
- Preexisting neurological or psychiatric disease that would confound the neurological functional evaluations;
- Multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation);
- Brain tumors with mass effect (except meningiomas) that are radiographically pleasant;
- Intracranial aneurysm, arteriovenous malformation;
- Any terminal illness with life expectancy less than 6 months;
- Unlikely to be available for 90-day follow-up.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xinqiao Hospital of Chongqinglead
- The First Affiliated Hospital of Hainan Medical Universitycollaborator
- Dalian Central Hospitalcollaborator
- Huai'an First People's Hospitalcollaborator
Study Sites (8)
Yijishan Hospital of Wannan Medical College
Wuhu, Anhui, 241000, China
Xinqiao Hospital of Army Medical University
Chongqing, Chongqing Municipality, 400037, China
Wuyi Traditional Chinese Medicine Hospital
Jiangmen, Guangdong, 529000, China
The First Affiliated Hospital of Hainan Medical University
Haikou, Hainan, 570000, China
Huai'an First People's Hospital
Huai'an, Jiangsu, 223001, China
The 904th Hospital of CPLA
Wuxi, Jiangsu, 214000, China
Jingdezhen First People's Hospital
Jingdezhen, Jiangxi, 333000, China
Dalian Central Hospital
Dalian, Liaoning, 116000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 27, 2022
First Posted
February 9, 2022
Study Start
December 12, 2024
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
October 31, 2027
Last Updated
December 26, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
- Time Frame
- Related papers published 6 months later, the IPD will be shared
- Access Criteria
- yangqwmlys@163.com
study data without patient information